|

Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer

RECRUITINGN/ASponsored by Copenhagen University Hospital at Herlev
Actively Recruiting
PhaseN/A
SponsorCopenhagen University Hospital at Herlev
Started2023-01-01
Est. completion2027-01
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05788744

Summary

The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Sub-study 1: Suspicion of PDAC tumor stage I-III, scheduled for pancreatic resection, with or without preoperative neoadjuvant chemotherapy.
* Sub-study 2: .

  * PDAC tumor stage I-III
  * Has received intended curative resection (R0/R1) of PDAC
  * No signs of local recurrence or metastatic disease at a CT scan 4 months after the operation

Exclusion Criteria:

* Other cancers (excluding skin cancer other than melanoma) later than 3 years before inclusion
* Patients who are unlikely to comply with the protocol, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study

Conditions2

CancerResectable Pancreatic Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.